ORBIT (Oncology Research for Biologics and Immunotherapy Translation) is a novel organization within the MD Anderson Cancer Center, Houston, Texas, with the mission of making MDACC a recognized leader in the discovery and development of innovative biologics that help patients to prevail over cancer disease. ORBIT is a centralized MDACC organization that will guide, inform, accelerate and execute the translation of novel discoveries into clinically relevant cancer bio-therapeutics. We are committed to biologics development with industry standard and aim line of sight for combining scientific excellence with commercialization.
The successful candidate will join the in vivo group efforts in the characterization and development of monoclonal antibodies including those that function as immune modulators for the treatment of cancer. S/he will contribute to the pharmacology and toxicology (in vitro, ex vivo and in vivo) studies for multiple research programs across the different stages of pre-clinical drug discovery. Experience in the pharmaceutical or biotech industry is preferred.
•Under minimal supervision, perform in vivo studies for target validation, drug efficacy, PK/PD/efficacy relationship in the area of oncology and tumor immunology.
•Under minimal supervision to develop new in vitro assays and contribute to the ex vivo analysis of tumor or immune cells by FACS, IHC, ELISA, western blot to identify and validate biomarkers and elucidate MOA in vivo.
•Independently plan, execute, analyze, and document experiments, manage multiple in vitro/in vivo/ex vivo experiments simultaneously.
•Comply with regulatory requirements and IACUC protocol implementation.
•Work in a team environment and, as needed, train new personnel hands-on.
- Employee Status: Regular
- Minimum Salary: US Dollar (USD) 48,000
- Midpoint Salary: US Dollar (USD) 88,800
- Maximum Salary : US Dollar (USD) 129,600